FREM1 Polyclonal antibody

FREM1 Polyclonal Antibody for WB, IF, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IF, IHC, ELISA

Conjugate

Unconjugated

Publications

2

Cat no : 13086-1-AP

Synonyms

C9orf143, C9orf145, C9orf154, FREM1, Protein QBRICK, QBRICK, RP11 439N12.3

---

Validation Data Gallery

• 

  WB analysis of human plasma using 13086-1-AP

  human plasma were subjected to SDS PAGE followed by western blot with 13086-1-AP (FREM1 Antibody) at dilution of 1:300 incubated at 4 degree celsius over night.

• 

  WB analysis of HepG2 using 13086-1-AP

  HepG2 cells were subjected to SDS PAGE followed by western blot with 13086-1-AP (FREM1 Antibody) at dilution of 1:300 incubated at 4 degree celsius over night.

• 

  IHC staining of human liver cancer using 13086-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 13086-1-AP (FREM1 Antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human liver cancer using 13086-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver cancer tissue slide using 13086-1-AP (FREM1 Antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human breast cancer using 13086-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 13086-1-AP (FREM1 Antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human breast cancer using 13086-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 13086-1-AP (FREM1 Antibody) at dilution of 1:50 (under 40x lens).

• 

  IF Staining of HepG2 using 13086-1-AP

  Immunofluorescent analysis of HepG2 cells using 13086-1-AP (FREM1 antibody) at dilution of 1:25 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

---

Tested Applications

• Positive WB detected in: human plasma tissue, HepG2 cells
• Positive IHC detected in: human liver cancer tissue, human breast cancer tissue; Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
• Positive IF detected in: HepG2 cells

Recommended dilution

• Western Blot (WB): WB : 1:200-1:1000
• Immunohistochemistry (IHC): IHC : 1:20-1:200
• Immunofluorescence (IF): IF : 1:10-1:100

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Published Applications

• WB: See 1 publications below
• IHC: See 1 publications below

Product Information

13086-1-AP targets FREM1 in WB, IF, IHC, ELISA applications and shows reactivity with human samples.

• Tested Reactivity: human
• Cited Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: FREM1 fusion protein Ag3617
• Full Name: FRAS1 related extracellular matrix 1
• Calculated Molecular Weight: 2179aa, 244 kDa, 149.3 kDa
• Observed Molecular Weight: 40-43 kDa, 70-80 kDa
• GenBank Accession Number: BC031064
• Gene Symbol: FREM1
• Gene ID (NCBI): 158326
• RRID: AB_2877915
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

FREM1, C9orf143, C9orf145, C9orf154 and QBRICK, is an extracellular matrix protein that plays a role in epidermal differentiation and is required for epidermal adhesion during embryonic development. This antibody recognizes isoform 1 (244 kDa), isform 2 (80 kDa) and isoform 3 (43 kDa).

Publications

Species	Application	Title
human	WB	Aging (Albany NY); TILRR (FREM1 isoform 2) is a prognostic biomarker correlated with immune infiltration in breast cancer.; Authors - Xiao-Yi Xu
human	IHC	Cancer Med; Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.; Authors - Han-Ning Li